Cutaneous Vasculitis: When Blood Vessels Become Inflamed

Clinical Overview

Cutaneous vasculitis represents inflammation of blood vessel walls in the skin resulting from immune complex deposition, drug reactions, infections, or malignancy, presenting with characteristic palpable purpura and evolving into necrotic lesions. The condition encompasses diverse etiologies with leukocytoclastic vasculitis representing the most common small-vessel vasculitis affecting skin. Cutaneous manifestations often precede systemic involvement, providing early recognition opportunity. Palpable purpura distinguishes vasculitis from non-inflammatory petechiae through presence of inflammation causing lesion elevation and tenderness. The clinical course varies from self-limited disease resolving within weeks to chronic recurrent disease requiring ongoing immunosuppression. Accurate diagnosis requires skin biopsy confirming vasculitic changes with neutrophilic infiltration and fibrinoid necrosis of vessel walls. Treatment decisions depend on disease severity, extent, and presence of systemic manifestations.

Epidemiology

Cutaneous vasculitis represents approximately 5-10% of all vasculitis cases, with small-vessel cutaneous vasculitis being most common form. Leukocytoclastic vasculitis demonstrates annual incidence of approximately 40-60 cases per million population. Peak incidence occurs in adults aged 40-60 years though disease can present at any age. Females demonstrate slightly higher incidence than males. Medication-induced vasculitis accounts for 10-20% of cases with antibiotics (particularly penicillins and sulfonamides), NSAIDs, and allopurinol being frequent triggers. Infections including streptococcal pharyngitis, viral infections, and bacterial endocarditis trigger vasculitis in 10-20% of cases. Malignancy-associated vasculitis occurs in 5-15% of cases with hematologic malignancies being most frequent. Idiopathic cutaneous vasculitis accounts for 40-50% of cases. Seasonal variation occurs with increased incidence in fall and winter months.

Pathophysiology

Cutaneous vasculitis develops through immune complex deposition in small-vessel walls triggering complement activation and neutrophil recruitment. Type III hypersensitivity reaction involves circulating immune complexes depositing in postcapillary venules of dermis and subcutis. Complement activation through classical pathway generates C3a and C5a anaphylatoxins recruiting neutrophils to lesion sites. Neutrophils release enzymes and reactive oxygen species causing vessel wall damage and fibrinoid necrosis. In leukocytoclastic vasculitis, massive neutrophilic infiltration surrounds involved vessels with characteristic karyorrhexis (nuclear fragmentation) from leukocyte death. Direct immunofluorescence reveals IgG, IgM, IgA, and complement deposition in vessel walls. The specific trigger (drug, infection, malignancy, or idiopathic) determines antigen within immune complexes. Some medications act as haptens triggering antibody production. Infections provide pathogenic antigens. Malignancies produce circulating antigens creating immune complexes.

Clinical Presentation

Cutaneous vasculitis presents as palpable purpura appearing in crops over days, typically on lower extremities and buttocks representing areas of dependent hydrostatic pressure. Individual lesions begin as erythematous papules evolving to petechiae with surrounding palpable induration. The purpura does not blanch with pressure distinguishing it from urticarial lesions. As disease progresses, lesions may develop central hemorrhage, ulceration, and necrosis. Systemic symptoms occur variably with fever, malaise, and arthralgia in 30-50% of cases. Arthritis affecting knees and ankles develops in some patients. Abdominal pain suggesting gastrointestinal involvement occurs in 10-15% of cases. Renal involvement manifests as hematuria and glomerulonephritis in 5-10% of cases. Pulmonary involvement remains rare in cutaneous vasculitis. The lesions resolve over 4-6 weeks typically with residual hyperpigmentation or hypopigmentation.

Diagnosis

Diagnosis requires skin biopsy from fresh lesion (preferably less than 48 hours old) demonstrating characteristic histopathology. Histologic findings include neutrophilic infiltration of small vessel walls (capillaries, venules) in dermis with fibrinoid necrosis, red blood cell extravasation, and neutrophilic debris. Leukocytoclasia represents hallmark finding with nuclear fragmentation from neutrophil death. Direct immunofluorescence on perilesional normal skin reveals immune complex deposition (IgG, IgM, IgA, C3) in small vessel walls. Indirect immunofluorescence and circulating immune complex measurement less commonly performed. Laboratory evaluation includes complete blood count (normal or mild elevation), urinalysis screening for hematuria, serum creatinine assessing renal function, and inflammatory markers. Infectious serology including streptococcal antibodies (ASO titer, anti-DNase B) assists in identifying streptococcal triggers. Connective tissue disease screening with ANA, rheumatoid factor, and complement levels helps exclude systemic diseases. Medication review identifies possible drug triggers.

Treatment Algorithm

Treatment depends on disease severity and systemic involvement. Mild cutaneous-limited disease often resolves spontaneously with symptomatic care including leg elevation, compression, and NSAIDs. Topical corticosteroids applied to lesions provide symptomatic relief. Identification and discontinuation of triggering medications essential when drug-induced disease identified. Streptococcal infection treatment with penicillin therapy may halt disease progression. Moderate disease with systemic symptoms or persistent lesions warrants systemic corticosteroids. Prednisone 0.5-1 mg/kg daily (40-60 mg) produces improvement within days with gradual taper over weeks. Dapsone 100-150 mg daily provides adjunctive therapy with neutrophil-suppressing effects. Colchicine 1-2 mg daily benefits some patients through anti-inflammatory mechanisms. Severe disease with renal or pulmonary involvement requires hospitalization and aggressive therapy including methylprednisolone 1 gram IV daily and possible plasma exchange. Immunosuppressive agents including azathioprine or mycophenolate mofetil may be necessary for refractory disease.

Prognosis

Prognosis for cutaneous vasculitis is generally favorable with 80-90% of cases resolving within 4-6 weeks. Complete resolution occurs in 60-70% of patients. Recurrent vasculitis develops in 10-15% of patients. Poor prognostic factors include systemic involvement (particularly renal disease), older age at onset, and presence of anti-C1q antibodies. Renal involvement portends more serious course with potential for progressive glomerulonephritis requiring aggressive immunosuppression. Residual hyperpigmentation persists in many patients long after active vasculitis resolves. Mortality remains low in cutaneous-limited disease but increases substantially with systemic vasculitis involving multiple organs.

When to See a Dermatologist

Patients with suspected vasculitis require dermatology evaluation for diagnostic confirmation via skin biopsy. Those with systemic manifestations warrant urgent evaluation and possible hospitalization. Renal involvement necessitates nephrology consultation and aggressive therapy.

Frequently Asked Questions

Q: Is cutaneous vasculitis dangerous?
A: Cutaneous-limited vasculitis carries excellent prognosis. However, systemic vasculitis involving organs is more serious.

Q: Will vasculitis return?
A: Approximately 10-15% of patients develop recurrent vasculitis after initial disease. Identification of triggers reduces recurrence risk.

Q: Can medications cause vasculitis?
A: Yes, medications including antibiotics, NSAIDs, and other drugs trigger vasculitis. Discontinuation typically halts disease progression.

References

  1. Carlson JA. The histopathologic spectrum of cutaneous leukocytoclastic vasculitis. Am J Dermatopathol. 2006;28(2):161-173.
  2. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1-11.
  3. Schroeter AL, Diaz-Perez JL, Winkelmann RK, et al. Necrotizing vasculitis associated with lethal course and immune complex deposition. Arch Dermatol. 1971;104(3):254-259.
  4. Carlson JA, Chen KR. Cutaneous vasculitis: review and classification. J Am Acad Dermatol. 2006;54(3):374-396.
  5. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med. 1990;113(9):656-663.
  6. Sais G, Vidaller A, Jucglà A, et al. Characterization of IgA immune complexes in IgA vasculitis (Henoch-Schönlein purpura). Clin Exp Immunol. 1997;110(1):30-36.
  7. Kauffman LD, Harmon RG, Hanson RG, et al. Cutaneous vasculitis in systemic lupus erythematosus: a case report. Arthritis Rheum. 1979;22(9):1018-1022.
  8. Sams WM Jr, Thorne EG, Small P, et al. Leukocytoclastic vasculitis. Arch Dermatol. 1976;112(3):321-326.
  9. Mathieu A, Cauli A, Fabbri M, et al. Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol. 1995;7(4):272-279.
  10. Levine M, Khalidi N, Calabrese L. Cutaneous manifestations of vasculitis. Int J Dermatol. 2009;48(10):1026-1036.